Abstract:The myeloid-derived suppressor cell (MDSC)-mediated immunosuppressive tumor microenvironment (TME), where tumor hypoxia counts for much, has greatly compromised the outcome of cancer immunotherapy. Here, we demonstrated a strategy for selectively clearing intratumoral MDSCs. Specifically, 2-[2-[2-chloro-3-[(1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-propylindolium iodide (IR-780) and metformin (Met) were coloaded into mesoporous silica nanoparticles (MSNs) with CeO2 as the gatekeepers. Controlled release of cargos was achieved upon etching CeO2 with endogenous H2O2. Apart from the drug release, oxygen (O2) was also generated in this process. Importantly, the engagement of Met significantly inhibited mitochondrial respiration, thus working like an O2 economizer. Consequently, the populations and functions of tumor-infiltrated MDSCs were both dramatically reduced through selective alleviation of hypoxia at tumor sites, thus contributing to boosted immune responses. Additionally, the accumulated O2 enhanced IR780-mediated photodynamic therapy, which synergistically strengthened the antitumor efficacy of the platform. To the best of our knowledge, this is the first time to employ an O2-generated and -economized nanoplatform for selectively anergizing MDSC-mediated immunosuppression. We expect that this strategy will shed new light on the clinical cancer immunotherapy treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c18180?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c18180</a>.In vitro release profile of IR780 and Met from CeO2@/Met nanoparticles in plasma. Degradation of H2O2 by CeO2 NPs and the release of O2. Positive area of Ki-67 in tumor tissues after indicated treatments. Positive area of TUNEL in tumor tissues after indicated treatments. Survival curves of B16F10 tumor-bearing mice that received indicated treatments as displayed. Plasma concentration–time curves of CeO2@/Met in mice after intravenous injection. In vivo tissue distribution in B16F10 tumor-bearing mice intravenously injected with indicated treatments at different time points. Quantification of the metastatic nodules on the lung surface of mice under different treatments. Q-PCR analyzed the mRNA level of HIF-α in tumor tissues from B16F10 tumor-bearing mice subjected to indicated treatments. Relative intensity of HIF-1α protein expression by western blotting. Standardized uptake values (SUVs) in solid tumor regions obtained from in vivo PET images taken at 1 h after the injection of 18F-MISO. Relative quantification of MDSCs (CD11b+Gr-1+) in tumor tissues following different treatments. Relative quantification of CTLs (CD3+CD8+) in tumor tissues following different treatments. ELISA assay for IL-10 and TGF-β. Relative intensity of PD-L1 protein expression by western blotting. Histology of the mouse organs collected 21 days after the intravenous injection of CeO2@/Met (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c18180/suppl_file/am0c18180_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Bypassing the Immunosuppression of Myeloid‐Derived Suppressor Cells by Reversing Tumor Hypoxia Using a Platelet‐Inspired Platform

Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets

Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles

Ultrasound-Driven Biomimetic Nanosystem Suppresses Tumor Growth and Metastasis through Sonodynamic Therapy, CO Therapy, and Indoleamine 2,3-Dioxygenase Inhibition

Dual Oxygen-Supply Immunosuppression-Inhibiting Nanomedicine to Avoid the Intratumoral Recruitment of Myeloid-Derived Suppressor Cells

Defeating Relapsed and Refractory Malignancies Through a Nano-Enabled Mitochondria-Mediated Respiratory Inhibition and Damage Pathway

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief

Defeating Melanoma Through a Nano-Enabled Revision of Hypoxic and Immunosuppressive Tumor Microenvironment.

Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy

ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.

Selective Manipulation of the Mitochondria Oxidative Stress in Different Cells Using Intelligent Mesoporous Silica Nanoparticles to Activate On‐Demand Immunotherapy for Cancer Treatment

"Butterfly-effect" nano-platforms for cascade immune amplification and tumor clearance through multi-modal therapy and immune sensitization

Tumor Microenvironment-Activated Nanoparticles Loaded with an Iron-Carbonyl Complex for Chemodynamic Immunotherapy of Lung Metastasis of Melanoma In Vivo

Rationally Integrated Precise ER‐targeted And Oxygen‐compensated Photodynamic Immunostimulant for Immunogenicity‐boosted Tumor Therapy

High Intensity Focused Ultrasound-Responsive and Ultrastable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial–Mesenchymal Transition

A multifunctional nanosystem catalyzed by cascading natural glucose oxidase and Fe3O4 nanozymes for synergistic chemodynamic and photodynamic cancer therapy